Working Together to Define Antibiotic Appropriateness: Point Prevalence Survey in 47 Intensive Care Units from 12 US Hospitals, Partnership for Quality Care, March 2017

Citation

Published Version
doi:10.1093/ofid/ofx163.539

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493220

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
rational policy planning. We developed a mathematical model to describe antimicrobial use and demonstrate how it could be used in a model-driven decision support system.

Methods. We developed a discrete-time Markov chain model to describe antimicrobial use as a function of the following parameters: Choice decisions to start antibiotics on admission or after, Change decisions to stop antibiotics, and Completion decisions to discharge patients whether they were on or off antimicrobials. Partial derivatives were used to predict the extent to which antimicrobial use would respond to changes in each parameter. We used Veterans Affairs Bar Code Medication Administration data from 2010 to estimate parameters, as well as antimicrobial use using National Healthcare Safety Network (NHSN) definitions. Categories of anti-microbial-resistant Staphylococcus aureus (MRSA), broad community, broad hospital, and surgical site infection prophylaxis (SSIP) from NHSN were also used. Because of certain assumptions made when estimating parameters, we used non-linear regression to adjust them using data from year 2010. We then applied our model to predict antimicrobial use from 2013 parameters and compared with actual use with Pearson’s correlation coefficient.

Results. Correlation of predicted and actual antimicrobial use was 0.97, 0.99, 0.95, and 0.92 (using NHSN category order above; Figure 1). As a conservative estimate, the correlation of yearly changes between predicted and actual antimicrobial use for all categories was 0.75. For > 99% of all combinations of medical center, antimicrobial category, and year, decreasing the probability of starting antimicrobials had the most impact on measured antimicrobial use.

Conclusion. Our mathematical model is highly predictive of antimicrobial use and can be used to anticipate how much changes in decision points might lead to changes in antimicrobial use. Given the parameter space that most VA medical centers occupy, not starting antimicrobials appears to have greatest impact on use.

Disclosures. All authors: No reported disclosures.

685. Working Together to Define Antibiotic Appropriateness: Point Prevalence Survey in 47 Intensive Care Units from 12 US Hospitals, Partnership for Quality Care, March 2017
Kavita K. Trivedi, MD1; Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA2; Lilian M. Abbo, MD1; Arjun Srinivasan, MD, FSHEA1; Rachel Bartash, MD1; Fred Cassera, RPh3; Jorge Fleisher, MD4; David W. Kubiak, PharmD, BCPS (AQ ID)5; Alyssa R. Leteurtreau, MD, MPH, Priya Nori, MD6; Stephen Parodi, MD, FIDSA1; Laura Aragon, PharmD, BCPS (AQ ID)7; Eliza Dollard, PharmD7; Christina Gagliardo, MD1; Monica Ghitan, MD, FIDSA8; Amber Giles, PharmD9; Suri Mayer, PharmD10; Jennifer Quevedo, PharmD11; Gunter Rieg, MD12; Galina Shteyman, PharmD, BCPS13; Jaclyn Vargas, MD14; Shannon Kelley, MBA15 and Phyllis Silver, MD16; Trivedi Consults, LLC, Berkeley, California; 1Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York; 2Infectious Disease, University of Miami-Jackson Memorial Hospital, Miami, Florida; 3Centers for Disease Control and Prevention, Atlanta, Georgia; 4Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York; 5Maimonides Medical Center, Brooklyn, New York; 6Infectious Diseases, Saint Elizabeth's Medical Center/ Tufts University, Boston, Massachusetts; 7Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 8Infectious Diseases, Montefiore Medical Center, Bronx, New York; 9The Permanente Medical Group, Vallejo, California; 10Pharmacy, Jackson Memorial Hospital, Miami, Florida; 11Pediatrics, Maimonides Infant & Children's Hospital of Brooklyn, Brooklyn, New York; 12Division of Infectious Diseases, Maimonides Medical Center, Brooklyn, New York; 13University of Miami Hospital, Miami, Florida; 14Kaiser Permanente, Harbor City, California; 15Park Nicollet Methodist Hospital, Health Partners, St. Louis Park, Minnesota; 16Los Angeles County + UCLA Health, Southern California Medical Center, Los Angeles, California; 17Partnership for Quality Care, New York City, New York

Session: 74. Stewardship: Data and Program Planning
Thursday, October 5, 2017: 12:30 PM


686. Broad-Spectrum Antibiotic Use at Choice, Change, and Completion Throughout VA: Patterns of Initiation and De-escalation
Matthew Goetz, MD1,2,3; Christopher J. Graber, MD, MPH, FIDSA4,5; Makoto Jones, MD, MS1; Karl Madaras-Kelly, PharmD, M.P.H.1; Matthew Samore, MD, FSHEA1; Peter Glassman, MBBS, MSc1; and The Veterans Affairs Antimicrobial Use Learning Collaborative; 1Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; 2David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; 3Infectious Diseases, VA Greater Los Angeles Healthcare System, Los Angeles, California; 4Infectious Diseases Section, VA Greater Los Angeles Healthcare System, Los Angeles, California; 5Infectious Diseases, University of California at Los Angeles, Los Angeles, California; 6Internal Medicine, VA Salt Lake City Health Care System, Salt Lake City, Utah; 7Internal Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California; 8Infectious Diseases, University of California at Los Angeles, Los Angeles, California; 9Infectious Diseases, VA Greater Los Angeles Healthcare System, Los Angeles, California; 10Infectious Diseases, University of California at Los Angeles, Los Angeles, California

Background. A national assessment of antibiotic appropriateness in intensive care units (ICUs) with benchmarking was performed to assist antibiotic stewardship programs (ASPs) identify improvement opportunities.

Methods. A Centers for Disease Control and Prevention tool was adapted by an expert panel from the Partnership for Quality Care (PQC), a coalition dedicated to high quality care in US hospitals, to validate appropriate antibiotic use measurement via a point prevalence survey on a single day. Data were collected by ASP personnel at each hospital, de-identified and submitted in aggregate to PQC for benchmarking. Hospitals identified reasons for inappropriate antibiotic use by category and antibiotics misused.

Results. Forty-seven ICUs from 12 PQC hospitals participated: California (2), Florida (2), Massachusetts (3), Minnesota (1), and New York (4). Most hospitals identified as teaching (83%) with 252-1550 bed size (median: 563) and 20-270 licensed ICU beds (median: 70). All hospitals reported a formal ASP. On March 1, 2017, 362 (54%) of 667 patients in participating ICUs were on antibiotics (range: 8-81 patients); 1 patient was not assessed. Of the remaining 361 antibiotic regimens, 112 (31%) were identified as inappropriate from among all 12 hospitals (range: 9-82%) (Figure). The table displays inappropriate antibiotic use by ICU type. Reasons for inappropriate use included unnecessarily broad spectrum of activity (29%), duration longer than necessary (21%), and treatment of a non-infectious syndrome (19%). The antibiotic most commonly misused was vancomycin in 7 (58%) hospitals.

Conclusion. Up to 80% of antibiotic use in some ICUs is inappropriate, under-scoring the need for ASP interventions, standardized assessment tools and benchmarking. Strategies should focus on de-escalation of broad-spectrum antibiotics and reducing duration of therapy.

Disclosures. All authors: No reported disclosures.